Efficacy and mechanism of action of pyrotinib/arini

Pyrotinib Maleate (Pyrotinib Maleate) is a targeted drug for HER2-positive breast cancer. As a tyrosine kinase inhibitor, pyrotinib can effectively prevent the proliferation and spread of cancer cells by inhibiting the activation of HER2 receptors. HER2 (human epidermal growth factor receptor 2) is a receptor critical for cell growth and is overexpressed in approximately 20% of breast cancer cases. HER2-positive breast cancer is often characterized by highly aggressive tumors and difficult treatment. Therefore, therapeutic drugs targeting this target are of great significance.

Pyrotinib binds toHER2 receptor and inhibits its tyrosine kinase activity, thereby interrupting HER2-related downstream signaling pathways, inhibiting cell proliferation and inducing apoptosis. Specifically, pyrotinib can effectively inhibit the intracellular PI3K/Akt and MAPK pathways, which play an important role in the survival and proliferation of cancer cells. In addition to the treatment of HER2-positive breast cancer, pyrotinib has also shown potential in the treatment of other HER2-related cancers, such as HER2-positive gastric cancer and esophageal cancer.

In addition, pyrotinib has a strong ability to penetrate the blood-brain barrier and therefore exhibits superior effects in the treatment of patients with breast cancer brain metastases. Compared with other anti-HER2 drugs, pyrotinib has lower resistance and can still provide effective treatment, especially for those patients who have developed resistance to trastuzumab and lapatinib.

Because the targeting effect of pyrotinib is relatively precise, it can maintain good therapeutic effects while reducing side effects. Its side effects are relatively mild, with the most common side effects including gastrointestinal discomfort, rash, and liver function abnormalities, but are generally well tolerated.

Keyword tags: pyrotinib, Irene,HER2-positive breast cancer, targeted therapy, tyrosine kinase inhibitors, cancer treatment, drug mechanism, blood-brain barrier, breast cancer

Reference materials:https://www.hengrui.com/en/media/detail-60.html